Clinical Trial Update: Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating delayed adjuvant trastuzumab (Herceptin) in HER2-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED